Latest articles
NHSX: Combining the best talent from government, the NHS and industry
A new joint unit, NHSX, will be created to bring the benefits of modern technology to every patient and clinician. It will combine the...
Sygnature Discovery makes key appointments
Sygnature Discovery has made two key appointments, Dr Allan Jordan and Ms Louisa Jordison. Ms Jordison joins the independent integrated drug discovery and pre-clinical services...
KEYTRUDA results published for advanced renal cell carcinoma
MSD has announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, MSD’s anti-PD-1 therapy, in combination with Inlyta...